Drugs / AZD5153
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03527147 | Jun 2018 → Mar 2021 | diffuse large B-cell lymphoma | Acerta Pharma BV | Completed | No outcome recorded |
| Phase 1 | NCT03205176 | Jun 2017 → Mar 2021 | breast cancer, lymphoma, malignant pancreatic neoplasm, ovarian cancer +1 | AstraZeneca | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03013998 | Nov 2016 → Dec 2032 expected | acute myeloid leukemia | Beat AML, LLC | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-03-28 | AstraZeneca | Results Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017 astrazeneca.com ↗
Preclinical data uncovering a novel role for the bromodomain protein, BRD4, in regulating DNA replication-stress response, and the potential of the combination of the BRD4 inhibitor, AZD5153, and the ATR inhibitor, AZD6738, in the sustained delay of tumour growth (Abstract #1026) |
| 2016-04-14 | AstraZeneca | Results AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting astrazeneca.com ↗
Therapeutic activity of bivalent BRD4 inhibitor AZD5153 in haematological cancers |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-03-28 | AstraZeneca | Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017 astrazeneca.com ↗ |
| 2016-04-14 | AstraZeneca | AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting astrazeneca.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5153 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03527147 ↗ |
| Action | Inhibit | “BRD4 inhibitor” NCT03527147 ↗ |
| Modality | Small molecule | — CHEMBL4078100 ↗ |
| Route | Oral | “20 mg, oral, once daily” NCT03013998 ↗ |
| Target | BRD4 | “BRD4 inhibitor” NCT03527147 ↗ |